Key result
Ivabradine reduced the combined risk of cardiovascular death or hospitalization for worsening heart failure by 18% compared to placebo in patients with chronic heart failure and reduced ejection fraction.
Why the study?
Does ivabradine improve clinical outcomes in patients with heart failure and systolic dysfunction with heart rate ≥70 b.p.m in sinus rhythm?
Does ivabradine improve clinical outcomes in patients with heart failure and systolic dysfunction with heart rate ≥70 b.p.m in sinus rhythm?
This review summarizes data from the SHIFT trial demonstrating the efficacy of ivabradine across various subgroups of patients with HFrEF and elevated resting heart rate.
Answers are grounded in this paper and cite their sources.
May support ivabradine in HFrEF with elevated HR in sinus rhythm; leaves open need for updated prospective confirmation.
Resting heart rate is a strong predictor of mortality and cardiovascular outcome in patients with chronic heart failure. А specific inhibitor of the If current in the sinoatrial node ivabradine improves clinical outcome in patients with heart failure and systolic dysfunction with heart rate ≥70 b.p.m in repose and sinus rhythm. In this review we summarized data on the efficacy of ivabradine in different subgroups of patients, including patients with co-morbidities and severe heart failure.
No takes yet. Share an insight, caveat, or question.
Терещенко et al. (2016) conducted a review in Chronic heart failure with reduced ejection fraction (n=6,505). Ivabradine vs. Placebo was evaluated on Cardiovascular death or hospitalization for worsening heart failure (HR 0.82, 95% CI 0.75-0.90, p=<0.0001). Ivabradine reduced the combined risk of cardiovascular death or hospitalization for worsening heart failure by 18% compared to placebo in patients with chronic heart failure and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: